

External Funding Guidance Document

Please review the following eligibility criteria before making a submission:

- Novartis provides funding to UK-based organisations in our current areas of interest:
 - Solid tumours
 - Haematology
 - Cardiovascular
 - Immunology
 - Neuroscience

If your request is not aligned to our therapeutic areas, please contact us via email funding.uk@novartis.com

- Funding will only be granted to legitimate organisations, never to individuals or political parties, and must have clear and transparent objectives.
- Funding is provided without the intent to receive any benefit in exchange.
- Funding cannot be provided to underwrite a commercial business, generate income, pay for employee salary or support fundraising activities.
- Funding must not interfere with the independence of the recipients. Nothing may be offered or provided to an external stakeholder that is intended to have an inappropriate influence on the stakeholder's decision to prescribe, dispense, recommend, purchase, supply or administer medicinal products.
- Funding cannot be provided or be considered for activities which occur before the request date.
- Evidence of performance from previous year's funding must be submitted before a new application can be requested.
- The provision of funding to healthcare organisations, patient organisations and patients must be publicly disclosed as transfers of value.
- All applications are monitored for reporting adverse events. You agree to be contacted should your completed application contain information relevant to our adverse event reporting commitments.

Submission Process

Applications must be submitted at least 3 months prior to the activity start date.

- Grant requests must be submitted via the online application system located on the Novartis UK [website](#)
- Charitable donation requests must be submitted via email using the template available on the Novartis UK [website](#)
- All requests are evaluated by an internal review committee which may take up to 3 months. Requests are assessed on the value to patients, healthcare, the advancement of medical and scientific knowledge and / or community impact.

If a request is approved, you will receive a confirmation email and a Funding Agreement. Novartis requires that the Agreement be returned within the identified timelines. Funding will not be provided if the signed Agreement is not returned before the activity start date.

In the event a request is declined, you will receive a notification email from Novartis. If requested, we will try to provide feedback as to why the request was declined.

Post-Funding Process

Depending on the nature of the funding, evidence of performance will be requested to confirm the funds were used for the intended purpose. You will be asked to provide supporting documentation to provide evidence that the funds were used (i.e. agenda or invitation for events, invoices or documents created for projects, etc.). You may also be asked to provide a financial reconciliation of the expenditure incurred against the budget. Failure to provide the requested information within required timelines may result in future requests being declined.

Further Information

The personal information that you submit in your application will be used by Novartis for the purposes of evaluating the funding request and any associated disclosure. Any and all uses will comply with the Novartis Data Privacy Policy and all applicable laws.

UK | July 2023 | 291195